Closing Market Summary: Stocks End Down Week on Upbeat Note
The stock market ended a defensive week on an upbeat note. The S&P 500 gained 1.1% to narrow its weekly decline to 0.5% while the Nasdaq (+1.3%) outperformed slightly today, but lost 1.7% since last Friday.
The final session of the week was very quiet with the bulk of the action taking place at the open when the S&P 500 spiked above its 50-day moving average (2,090). The benchmark index spent the bulk of the day near its morning high, but punched through that level during afternoon action to complete a full retracement of Thursday's decline.
Nine of ten sectors posted gains with materials (+1.7%) ending the day and the week (+2.0%) ahead of the remaining sectors. Today, the growth-sensitive group received support from Monsanto (MON 118.42, +4.46) as the stock spiked 3.9% after Bloomberg reported the company has approached Syngenta (SYT 77.95, +10.91) about a potential takeover. Steelmakers also contributed to the sector's strength with Market Vectors Steel ETF (SLX 35.74, +0.49) climbing 1.4%.
Meanwhile, the other commodity-related sector—energy—spent the bulk of the session in the red, but turned positive during the afternoon. The sector added 0.3% today and finished the week with a 1.1% gain. Crude oil weighed on the sector in the early going, but the energy component narrowed its loss to 0.8% by the close to settle at $59.15/bbl. WTI crude recovered a portion of its decline after the latest Baker Hughes Rig Count showed that the pace of decline in active oil and gas rigs slowed to 27 from 31 observed last week.
However, crude oil could not return into the green as an uptick in the greenback weighed on the dollar-denominated commodity. To that point, the Dollar Index (95.15, +0.55) added 0.6% and registered its first advance in eight days after the previous seven sessions saw the index slide 3.6%.
Outside of energy, the financial sector (+0.8%) was the only other cyclical group that ended the day behind the broader market. Meanwhile, the top-weighted technology sector (+1.5%) outperformed even as LinkedIn (LNKD 205.21, -46.92) plunged 18.6% after its cautious guidance overshadowed a one-cent beat. However, LinkedIn's weakness was offset by most large cap names with the likes of Apple (AAPL 128.95, +3.80), Oracle (ORCL 44.37, +0.75), and Intel (INTC 33.42, +0.87) gaining between 1.7% and 3.0%.
Over on the countercyclical side, only the health care sector (+1.3%) finished the day ahead of the S&P 500 with help from biotechnology. The iShares Nasdaq Biotechnology ETF (IBB 344.00, +10.34) spiked 3.1% after Gilead Sciences (GILD 105.03, +4.52) reported better than expected results.
Treasuries retreated throughout the day, sending the 10-yr yield higher by eight basis points to 2.11%.
Today's participation was below recent averages with roughly 720 million shares changing hands at the NYSE floor.
Economic data included Construction Spending, ISM Index, and Michigan Sentiment:
* Construction spending declined 0.6% in March after increasing an upwardly revised 0.1% (from -0.1%) in February while the consensus expected an increase of 0.4%
* Private construction spending increased 0.3% in March after declining 0.3% in February * Despite a rebound in the new housing starts, private residential construction declined 1.6% in March after increasing 0.2% in February
* The ISM Manufacturing Index was unchanged and remained at 51.5 in April while the Consensus expected an increase to 51.9
* Even though the overall index did not strengthen as the consensus expected, the key production and order readings showed improvement
* The Production Index increased to 56.0 in April from 53.8 in March * The New Orders Index increased to 53.5 from 51.8
* The University of Michigan Consumer Sentiment Index was unrevised in the final April reading after sentiment rose from 93.0 in March to 95.9 in April while the consensus expected a revision up to 96.0
* Unlike the Conference Board's Consumer Confidence Index, which declined in April, relatively higher gasoline prices and volatility in the equity markets had no adverse effects on the Consumer Sentiment Index
Monday's data will be limited to the 10:00 ET release of the Factory Orders report for March (Briefing.com consensus 2.1%).
* Nasdaq Composite +5.7% YTD * S&P 500 +2.4% YTD * Russell 2000 +1.9% YTD * Dow Jones Industrial Average +1.1% YTD
+------------------------------------------------------------------------------+
BFW 05/01 21:04 Abbvie Extends Exchange Offer to Buy Pharmacyclics Until May 15 BFW 05/01 21:01 *ABBVIE EXTENDS EXCHANGE OFFER TO BUY PHARMACYCLICS BN 05/01 21:00 *ABBVIE SAYS 51.5M PHARMACYCLICS SHRS TENDED AS OF MAY 1 BN 05/01 20:59 *ABBVIE EXTENDS EXCHANGE OFFER TO MAY 15 BN 05/01 20:59 *ABBVIE EXTENDS EXCHANGE OFFER TO BUY PHARMACYCLICS BN 05/01 20:59 *ABBVIE EXTENDS EXCHANGE OFFER TO BUY PHARMACYCLICS,
+------------------------------------------------------------------------------+
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2015-05-01 20:59:10.387 GMT
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
PR Newswire
NORTH CHICAGO, Ill., May 1, 2015
NORTH CHICAGO, Ill., May 1, 2015 /PRNewswire/ -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 15, 2015.
The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 1, 2015, a total of approximately 51,470,840 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer.
All other terms and conditions of the exchange offer remain unchanged.
About AbbVie Inc.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Forward-Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements include the expected structure and timetable for the transaction between AbbVie and Pharmacyclics. The statements in this release are based upon current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include risks and uncertainties related to, among other things: failure to satisfy the conditions to consummate the offer and the merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the failure of the offer or the merger to close for any other reason; the amount of the costs, fees, expenses and charges related to the offer and the merger; general economic and business conditions, global economic growth and activity; industry conditions; changes in laws or regulation; and other factors beyond the companies' control as well as the risk factors and other cautionary statements described in AbbVie's and Pharmacyclics' filings with the SEC. Please refer to the Risk Factors section of AbbVie's Registration Statement on Form S-4, as filed on March 23, 2015 for a further list and description of additional business risks, uncertainties, and other factors that may affect these statements. All subsequent written and oral forward-looking statements attributable to AbbVie or Pharmacyclics or any person acting on their behalf are qualified by the cautionary statements in this section.
Important Additional Information
This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of Pharmacyclics, nor is it a substitute for the Registration Statement on Form S-4 and tender offer materials that AbbVie filed with the Securities and Exchange Commission ("SEC") on March 23, 2015, each as amended.
Investors and security holders of Pharmacyclics are urged to read the tender offer statement on Schedule TO, filed on March 23, 2015 (as amended, the "Schedule TO"), the Registration Statement on Form S-4, as filed on March 23, 2015 (as amended, the "Registration Statement"), and the solicitation/recommendation statement filed by Pharmacyclics on Schedule 14D-9, filed on March 23, 2015 (as amended, the "Schedule 14D-9"). The tender offer materials (including an offer to purchase, letter of transmittal and related tender offer documents), the Registration Statement and the Schedule 14D-9 contain important information which should be read carefully before any decisions are made with respect to the Offer.
In addition to the Schedule TO, the Schedule 14D-9 and the Registration Statement described above, AbbVie and Pharmacyclics file annual, quarterly and current reports, proxy statements and other information with the SEC. The Schedule TO, the Schedule 14D-9, the Registration Statement and any other relevant materials, and any other documents filed with the SEC by AbbVie or Pharmacyclics, are available without charge at the SEC's website at www.sec.gov , or from the companies' websites, at www.abbvieinvestor.com and http://www.pharmacyclics.com, respectively.
Free copies of the exchange offer materials (including the Registration Statement and the Schedule TO) are also available on AbbVie's website at www.abbvieinvestor.com and copies of the Schedule 14D-9 are available on Pharmacyclics' website http://www.pharmacyclics.com. Copies of the exchange offer materials (including the Registration Statement and the Schedule TO) may also be obtained free of charge from Georgeson Inc., the information agent for the exchange offer, by calling, toll-free, (888) 680-1528 or emailing PCYC@georgeson.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbvie-extends-exchange-offer-to-acquire-pharmacyclics-inc-300076204.html
SOURCE AbbVie Inc.
Website: http://www.abbvie.com Contact: Media, Adelle Infante, 847-938-8745, or Investors, Liz Shea, 847-935-2211
-0- May/01/2015 20:59 GMT
+------------------------------------------------------------------------------+
SAP Said to Have Held Strategy Talks With Salesforce Last Year 2015-05-01 20:00:37.980 GMT
By Aaron Ricadela and Jack Clark (Bloomberg) -- The chief executive officers of SAP SE and Salesforce.com Inc. held discussions last year about possible strategic alliances between the two companies, people with knowledge of the matter said. The talks also included a potential acquisition of Salesforce by SAP, said one of the people, who asked not to be identified because the negotiations were private. The discussions between Salesforce Chairman and CEO Marc Benioff and SAP CEO Bill McDermott began after Benioff contacted McDermott via telephone before SAP reported quarterly earnings on April 17, 2014, said the person. Chi Hea Cho, a spokeswoman for San Francisco-based Salesforce, declined to comment. Nicola Leske, a spokeswoman for Walldorf, Germany-based SAP, declined to comment. It couldn’t be determined whether there are currently any takeover discussions between the two companies. Salesforce is working with financial advisers to help it field takeover offers after being approached by a potential acquirer, Bloomberg reported Wednesday. Salesforce was prompted to work with the financial advisers by a more recent overture from a company other than SAP, another person said. A takeover of Salesforce would be the largest ever for a software company. Acquiring the company would give any buyer a lead in the market for customer relationship management software, and credibility in cloud computing. Safra Catz, co-CEO of Salesforce rival Oracle Corp., said this week that an acquisition of Salesforce by a competitor would be good for Oracle. “It’ll cause a lot of disruption in that market,” she said and declined to comment on whether Oracle was interested in the company. Growth has been slowing in Salesforce’s main customer relationship management business, forcing the company to expand into other verticals such as marketing and analytics via a combination of acquisitions and new products. Oracle, Microsoft Corp. and other rivals have done the same. Salesforce’s revenue rose 32 percent in the fiscal year through January, compared with 33 percent in the prior year, and 35 percent the year before that.
For Related News and Information: Salesforce Revenue Outlook Tops Estimates on Enterprise Push Salesforce Would Be Priciest Big Tech Deal This Decade: Real M&A Oracle Co-CEO Catz Says Rival Buying Salesforce ‘Probably Good’ Salesforce Said to Work With Bankers to Field Inquiries Salesforce relative value: CRM US <EQUITY> RVG <GO> Salesforce revenue: CRM US <EQUITY> EM SALES <GO> Salesforce deals: CRM US <EQUITY> MADL <GO> Top Technology Stories: TTOP <GO>
To contact the reporters on this story: Aaron Ricadela in Frankfurt at +49-69-92041-156 or aricadela@bloomberg.net Jack Clark in San Francisco at +1-415-617-7034 or jclark185@bloomberg.net To contact the editors responsible for this story: Jillian Ward at +1-415-617-7261 or jward56@bloomberg.net; Kenneth Wong at +49-30-70010-6215 or kwong11@bloomberg.net Reed Stevenson, Tony Robinson
FireEye (+6%) leading cybersecurity stocks higher (HACK +1.1%) following upside Q1 results (43.65 +2.35)
FEYE +5.8%, CYBR +3.2%, QLYS +2%, PFPT +1.6%, PANW +1.5%, FTNT +1.5%, CHKP +0.6%, IMPV -0.6%.
Chevron beats by $0.56, reports revs in-line (111.09)
Reports Q1 (Mar) earnings of $1.37 per share, $0.56 better than the Capital IQ Consensus Estimate of $0.81; revenues fell 35.1% year/year to $34.56 bln vs the $34.72 bln consensus. Foreign currency effects increased earnings in the 2015 quarter by $580 mln, compared with a decrease of $79 mln a year earlier.
- First quarter earnings declined from a year ago due to sharply lower oil prices, which reduced revenue and earnings in our upstream business. - Downstream operations were strong, benefitting from lower feedstock costs and improved refinery reliability. - U.S. upstream operations incurred a loss of $460 mln in Q1 2015 compared to earnings of $912 mln from a year earlier, largely due to sharply lower crude oil realizations. Higher depreciation expenses, in part due to impairments, and lower natural gas realizations, were largely offset by higher crude oil production and lower operating expenses. - The company's average sales price per barrel of crude oil and natural gas liquids was $43 in Q1 2015, down from $91 a year ago. The average sales price of natural gas was $2.27 per thousand cubic feet, compared with $4.77 in last year's Q1. - Net oil-equivalent production of 699,000 barrels per day in Q1 2015 was up 59,000 barrels per day, or 9%, from a year earlier Production increased due to project ramp-ups in the Gulf of Mexico, the Permian Basin in Texas and New Mexico, and the Marcellus Shale in western Pennsylvania
Gapping up In reaction to strong earnings/guidance: WAVX +37.9%, OCN +13.2%, OXGN +12.2%, NTRI +10.1%, KCG +9%, ELLI +8.2%, TER +7.9%, LLNW +7.8%, LYG +6.9%, ATHN +6.1%, CENX +5.1%, AXL +4.7%, EXPE +4.5%, BRKS +4.5%, FEYE +4.4%, SWKS +4%, UVE +4%, AEM +3.4%, NTLS +3.4%, CEMP +3.2%, EEP +3.2%, MOBL +3%, SKYW +2.9%, NKTR +2.9%, NSU +2.9%, GILD +2.8%, GERN +2.5%, MXL +2%, MCO +1.8%, WU +1.6%, HABT +1.4%, BYD +1.4%, MNTA +1.4%, CVS +1.3%, LEG +1.2%, COHU +1.2%, CRC +1.1%, RGC +1.1%, THG +1.1%, CRC +1.1%, CHSP +1%, CBM +1%, FLR +0.8%
M&A news: SYT +16.6% (reports of Monsanto interest), ALTR +5.5% (report indicated that INTC was willing to go as high as $58 for its ALTR offer)
Other news: VLTC +11.9% (still checking), HERO +3.1% (announced extension of termination date of Hercules 261 contract), SRNE +2.7% (announced appointment of Mark Durand as CFO), AEHR +1.8% (announced an order receipt for an ABTS burn-in and test system from a Chinese customer), BHP +1.6% (BHP Billiton and Barbadoes sign exploration licences for two offshore blocks, Carlisle Bay and Bimshire), ELS +1.3% (filed mixed securities shelf offering), TSLA +1.2% (confirms it introduces Tesla Energy, a suite of batteries for homes, businesses, and utilities), CHSP +1% (acquired the Ace Hotel and Theater for $103 mln), MOS +1% (still checking), ALU +0.9% (slight rebound following yesterday's fall), LUV +0.8% (filed for offering of debt securities and common stock), FNMA +0.7% (released March 2015 monthly summary; Book of Business increased at a compound annualized rate of 0.4%), SCTY +0.7% (SolarCity and TSLA introduce affordable new energy storage services across the U.S.), THO +0.7% (acquired Postle Aluminum for ~$144 mln)
Analyst comments: CY +2.1% (upgraded to Strong Buy from Buy at Needham), ZAYO +1.9% (upgraded to Strong Buy from Outperform at Raymond James), WU +1.6% (upgraded to Outperform from Market Perform at Wells Fargo), CMG +0.9% (upgraded to Outperform from Market Perform at BMO Capital)
Gapping up
Gapping up In reaction to strong earnings/guidance: WAVX +37.9%, OCN +13.2%, OXGN +12.2%, NTRI +10.1%, KCG +9%, ELLI +8.2%, TER +7.9%, LLNW +7.8%, LYG +6.9%, ATHN +6.1%, CENX +5.1%, AXL +4.7%, EXPE +4.5%, BRKS +4.5%, FEYE +4.4%, SWKS +4%, UVE +4%, AEM +3.4%, NTLS +3.4%, CEMP +3.2%, EEP +3.2%, MOBL +3%, SKYW +2.9%, NKTR +2.9%, NSU +2.9%, GILD +2.8%, GERN +2.5%, MXL +2%, MCO +1.8%, WU +1.6%, HABT +1.4%, BYD +1.4%, MNTA +1.4%, CVS +1.3%, LEG +1.2%, COHU +1.2%, CRC +1.1%, RGC +1.1%, THG +1.1%, CRC +1.1%, CHSP +1%, CBM +1%, FLR +0.8%
M&A news: SYT +16.6% (reports of Monsanto interest), ALTR +5.5% (report indicated that INTC was willing to go as high as $58 for its ALTR offer)
Other news: VLTC +11.9% (still checking), HERO +3.1% (announced extension of termination date of Hercules 261 contract), SRNE +2.7% (announced appointment of Mark Durand as CFO), AEHR +1.8% (announced an order receipt for an ABTS burn-in and test system from a Chinese customer), BHP +1.6% (BHP Billiton and Barbadoes sign exploration licences for two offshore blocks, Carlisle Bay and Bimshire), ELS +1.3% (filed mixed securities shelf offering), TSLA +1.2% (confirms it introduces Tesla Energy, a suite of batteries for homes, businesses, and utilities), CHSP +1% (acquired the Ace Hotel and Theater for $103 mln), MOS +1% (still checking), ALU +0.9% (slight rebound following yesterday's fall), LUV +0.8% (filed for offering of debt securities and common stock), FNMA +0.7% (released March 2015 monthly summary; Book of Business increased at a compound annualized rate of 0.4%), SCTY +0.7% (SolarCity and TSLA introduce affordable new energy storage services across the U.S.), THO +0.7% (acquired Postle Aluminum for ~$144 mln)
Analyst comments: CY +2.1% (upgraded to Strong Buy from Buy at Needham), ZAYO +1.9% (upgraded to Strong Buy from Outperform at Raymond James), WU +1.6% (upgraded to Outperform from Market Perform at Wells Fargo), CMG +0.9% (upgraded to Outperform from Market Perform at BMO Capital)
Chevron prelim $1.37 vs $0.81 Capital IQ Consensus Estimate; revs $34.56 bln vs $34.72 bln Capital IQ Consensus Estimate